Brickell Biotech CFO resigns to fully commit to Edgewise Therapeutics
BOULDER — R. Michael Carruthers, the chief financial officer and head accountant for Brickell Biotech inc. (Nasdaq: BII), is resigning from the company to fully commit to fellow Boulder-based biopharmaceutical firm Edgewise Therapeutics Inc.
In a filing to the U.S. Securities and Exchange Commission Tuesday morning, the Boulder-based Brickell said Carruthers would resign effective at the end of the month.
Carruthers, a veteran finance officer of multiple Boulder-area clinical companies, was acting as an independent CFO consultant before joining Edgewise Therapeutics in September as its full-time CFO.
Brickell said it will hire…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Boulder-based publishing technology company Sovrn Holdings Inc. has named Will Duckworth its chief technology officer.
-
A Boulder fiber infrastructure company and broadband internet provider said it has raised $80 million…
-
Knowledge Factor Inc., a software-as-a-service company that provides cognitive science-based assessment, training and data analytics…
-
Tilled Inc., a Boulder payment-facilitation technology company, recently completed a $12.5 million investment round, bringing…
